NCT07221500
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07221500
Title A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Acronym DAYBreak CLL-201
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Nurix Therapeutics, Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | POL | GBR | FRA

Facility Status City State Zip Country Details
Colorado Blood Institute RECRUITING Denver Colorado 80218 United States Details
SCRI Oncology Partners RECRUITING Nashville Tennessee 37203 United States Details
Texas Oncology - Center South RECRUITING Austin Texas 78705 United States Details
CHU de Nantes RECRUITING Nantes 44000 France Details
Pratia Hematologia Sp. z o.o. RECRUITING Katowice 40-519 Poland Details
Pratia S.A. RECRUITING Krakow 30-225 Poland Details
Aidport Sp. z o.o. RECRUITING Skorzewo 60-185 Poland Details
Pratia Warszawa / Pratia MTZ RECRUITING Warsaw 02-172 Poland Details
The Royal Marsden NHS Foundation Trust RECRUITING London SW3 6JJ United Kingdom Details
The Christie NHS Foundation Trust RECRUITING Manchester M20 4BX United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field